Journal
BIOCHEMICAL PHARMACOLOGY
Volume 81, Issue 8, Pages 1004-1015Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2011.01.019
Keywords
mRNA stability; IL-6; Astrocytes; IL-1 beta; PKC; p38
Categories
Funding
- Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO)
- Ghent University GROUP-ID consortium
- Ghent University [BOF 01D31406]
Ask authors/readers for more resources
Uncontrolled expression of IL-6 in the central nervous system is associated with neurodegenerative pathology and glioma development. Astrocytes are the predominant source of IL-6 in the central nervous system, and they are characteristically susceptible to synergistic IL-6 expression. Combined beta-adrenergic and TNF-receptor triggering induces synergistic IL-6 expression in 1321N1 cells via a transcriptional enhancer mechanism. Here, we have investigated the molecular basis of the very potent super-synergistic IL-6 expression that is apparent after combined treatment of astrocytes with a beta-adrenergic agonist, isoproterenol, and the inflammatory cytokines TNF-alpha and IL-1 beta. We found that IL-1 beta treatment strengthens the IL-6 synergy by inducing a distinct stabilization of IL-6 mRNA. Surprisingly, the mRNA-stabilizing effect seems to be dependent on protein kinase C (PKC), but not on the prototypical mRNA-stabilizing kinase p38. Moreover, although the mRNA-binding protein HuR basally stabilizes IL-6 mRNA, the mRNA-stabilizing effect of IL-1 beta is independent of HuR. Our data using pharmacological inhibitors suggest PKC is an important modulator of IL-6 expression in the central nervous system and this might have therapeutic implications. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available